drugset / Trial / NCT00998049
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
NaSingle-groupOpen-labelTreatment
Summary
Rationale: Giving colony-stimulating factors, such as G-CSF and plerixafor helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored. Purpose: This phase II trial is studying how well plerixafor works in patients with multiple myeloma previously treated with lenalidomide and planning to undergo autologous stem cell transplant.
Timeline
- Start
- 2009-12
- Primary completion
- 2011-11
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Plerixafor | Small molecule | 160 mg/kg | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | 10 mg/kg | Subcutaneous |